CN1090942C - 一种用于治疗囊性肿瘤和血管瘤的复方磷酸液 - Google Patents
一种用于治疗囊性肿瘤和血管瘤的复方磷酸液 Download PDFInfo
- Publication number
- CN1090942C CN1090942C CN 94114274 CN94114274A CN1090942C CN 1090942 C CN1090942 C CN 1090942C CN 94114274 CN94114274 CN 94114274 CN 94114274 A CN94114274 A CN 94114274A CN 1090942 C CN1090942 C CN 1090942C
- Authority
- CN
- China
- Prior art keywords
- phosphoric acid
- liquid
- hemangioma
- cystic tumor
- compound recipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229910000147 aluminium phosphate Inorganic materials 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 208000012106 cystic neoplasm Diseases 0.000 title claims abstract description 17
- 201000011066 hemangioma Diseases 0.000 title abstract description 10
- 239000007788 liquid Substances 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002075 main ingredient Substances 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 230000003796 beauty Effects 0.000 abstract description 4
- 210000005081 epithelial layer Anatomy 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 206010011732 Cyst Diseases 0.000 description 12
- 208000031513 cyst Diseases 0.000 description 12
- 239000002775 capsule Substances 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 210000001847 jaw Anatomy 0.000 description 4
- 210000004373 mandible Anatomy 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 210000000589 cicatrix Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- GRIXGZQULWMCLU-UHFFFAOYSA-L disodium;7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].C12OCC(CSC=3N(N=NN=3)C)=C(C([O-])=O)N2C(=O)C1(OC)NC(=O)C(C([O-])=O)C1=CC=C(O)C=C1 GRIXGZQULWMCLU-UHFFFAOYSA-L 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 229960005491 sodium morrhuate Drugs 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000009146 rhinoscleroma Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- 206010006164 Branchial cyst Diseases 0.000 description 1
- 208000000529 Branchioma Diseases 0.000 description 1
- 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
- 208000010383 Dentigerous Cyst Diseases 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001031591 Mus musculus Heart- and neural crest derivatives-expressed protein 2 Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 208000002595 Radicular cyst Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 231100000429 cutaneous necrosis Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000001460 masseteric effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010063413 odontogenic cyst Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000028528 solitary bone cyst Diseases 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种不用手术、方便经济、疗效高的治疗囊性肿瘤和血管瘤用复方磷酸液。以人体主要成份磷酸为主要成份,采用注射方法来破坏囊性肿瘤和血管瘤的上皮层细胞,达到治愈的目的。本发明不用手术,操作简易,无副作用,无并发症,经济实用,益于美容。
Description
本发明涉及一种治疗囊性肿瘤和血管瘤的复方磷酸液。
囊性肿瘤和血管瘤是一种常见病,多发病。目前治疗囊性肿瘤和血管瘤的根治方法是外科手术摘除。手术会给病人造成痛苦和恐惧感,部分老弱病残者不能接受外科手术,同时手术疗法创伤大,危险大,易发生并发症,会破坏周围正常组织结构,影响正常生理功能,遗留疤痕,造成畸形,影响美容。费用高,工作强度大,还需要一定的技术水平。
目前治疗囊性肿瘤和血管瘤的其它方法如下所述:
一、治疗粘液囊肿的有:1、采用三氯醋酸注射疗法,效果不理想,不易操作,术后不良反映明显,很少应用。2、采用30%氯化钠,碘酊,5%鱼肝油酸钠,强的松尤,四环素等注射疗法,一次治愈率不高,效果不理想,鱼肝油酸钠术后肿痛反映明显。3、冷冻、激光疗法,此法将囊肿表层皮肤或粘膜一同破坏,组织损伤面积大,遗留疤痕,色素沉着,影响美容,并且仪器设备昂贵复杂,一般不能普及。
二、治疗血管瘤的方法有:1、激光,冷冻,鱼肝油酸钠等治疗方法。2、放射疗法,同位素贴敷,治愈率不高,毒性大,易导致放射性危害。
三、国外有采用冲洗法治疗下颌骨囊肿,此法需定期反复冲洗,待囊腔缩小后再用手术摘除。
以上方法虽有一定的疗效,但适应范围小,不能用于治疗各种类型的囊性肿瘤和血管瘤。本人在上述方法的启发下,首先分析了各种类型的囊性肿瘤和血管瘤的组织结构及其病理生长过程,找出其共性,又着手寻找一种无毒无副作用,经济易取,对各种囊性肿瘤和血管瘤采用注射方法都能达到治愈目的的新的药液。
囊性肿瘤外层是纤维性囊壁,内衬薄层上皮细胞,腔内充满透明或淡黄色液体。囊液是由上皮细胞分泌的,上皮层将囊腔与中胚层分隔,阻止两者之间的物质交换,除了部分水和盐外,液体不能被完全吸收,液体不断积聚,形成一种正压力,使囊腔逐渐扩大。只要破坏囊肿内衬上皮层,腔内液体不能积聚并被吸收,肉芽组织增生,充满囊腔,即可治愈。血管瘤是由许多内衬内皮的薄壁血管组成,属于腔内充满血液的多房性囊肿。
本发明的目的是提供一种不用手术、无副作用的治疗囊性肿瘤和血管瘤的复方磷酸液。
其技术解决方案为:
磷酸为该药液的主要成分,主要作用是破坏上皮层细胞,使之凝固坏死;少量的盐酸,作用是增强本药液的渗透性;适量的磷酸二氢钠起缓冲作用。
以配制100ml复方磷酸液为例,取磷酸45ml,盐酸5ml,磷酸二氢钠2g,蒸馏水50ml,制成混合均匀的药液。本发明的组成成分:磷酸为45%,盐酸为5%,磷酸二氢钠2g(每100ml药液),蒸馏水50%。磷酸是人体内主要成分之一,复方磷酸液酸度适宜,易于控制和操作,无毒无副作用,不会引起皮肤和粘膜损伤,并且有自限性,不会引起深部组织坏死,且药液注入腔内,作用2-4分钟后抽出,药物不在体内存留,不被身体吸收。
复方磷酸液的应用方法简易,局部麻醉后,囊腔穿刺,将囊液抽净,注入复方磷酸液,注入量应使囊腔充盈,以使囊壁均受作用,留药2-4分钟,药物抽出,再用灭菌水冲洗囊腔3-4次,最后将冲洗液抽出。操作过程中不要使针头拔出,勿使药液外溢。
复方磷酸液治疗囊性肿瘤和血管瘤的疗效显著。92年以来,本人采用自制复方磷酸液为患者治疗,经临床观察,取得了好的效果。见下表:
例数 | 一次治愈 | 二次治愈 | 无效 | 有效率% | 复发 | 复发率% | |
粘液囊肿 | 78 | 75 | 3 | 0 | 100 | 3 | 3.8 |
舌下囊肿 | 9 | 9 | 0 | 0 | 100 | 0 | 0 |
血管瘤 | 10 | 10 | 0 | 0 | 100 | 0 | 0 |
颈部软组织囊肿 | 18 | 15 | 2 | 1 | 94.4 | 0 | 0 |
颌骨囊肿 | 22 | 18 | 3 | 1 | 95.4 | 0 | 0 |
合计 | 137 | 127 | 8 | 2 | 98.5 | 3 | 2.2 |
注:1、2例无效者分别为含牙囊肿和皮样囊肿,因腔内含有不易被吸收
的物质。
2、粘液囊肿有三例复发,但从组织学的角度分析,不属复发,而是
再生。
用复方磷酸液治疗囊性肿瘤和血管瘤,经本人临床实用,具有其独特的优点:1、用注射法代替了传统的外科手术摘除法。治愈率高,安全度大。2、适用于治疗各种类型的囊性肿瘤及血管瘤。3、不会发生后遗症,如疤痕挛缩畸形、骨缺损畸形等。4、对不适应于外科手术的病人如贫血、患有系统性疾病、年老体弱等均可用此法治疗,临床检查生命征稳定。5、消除了病人恐惧感,易被患者所接受,治疗后无明显不适感。6、对周围组织器管无损伤破坏,不影响正常生理功能;不遗留疤痕,不影响美容。7、不同于外科手术需要一定的恢复期,无体克、出血、骨折等并发症,手术后即可恢复正常生活。8、经济、简易、便于推广,可节省费用90%以上。
下面介绍几份用复方磷酸液治疗的典型病历:
例一:
李××,女,25岁,工人,92年5月3日就诊。左下唇生一无痛性肿物1月余,向唇外突起,有异物感,未寻及明显诱因。触之囊状感。生米大,无触痛,粘膜无红肿。诊为粘液囊肿。穿刺抽出粘稠无色液体。注入复方磷酸液0.2ml,2分钟后冲洗。术后唇部无肿胀,1周后呈豆粒状硬结块,3周呈米粒状,1月后复查硬结块消失。
例二:
李××,女,6岁,于93年3月28日就诊。右舌下无痛性肿物半年余。查右口底有一约2×1cm突起性肿物,囊性感,粘膜无红肿,颌下导管口分泌正常。B超示1.9×2.3cm的囊性病变,怀凝双房性。前部造影为1.2×1.0cm阻光区。前部抽出约1.2ml淡黄色液体,后部穿刺抽出0.3ml更粘稠的淡白色液体,诊为双房性舌下囊肿。在前后囊腔内分别注入0.5ml及0.2ml复方磷酸液,2分钟冲洗。口底轻度肿胀3天,随访一年无复发。
例三:
赵××,女,23岁,农民,92年1月11日就诊。右颈部无痛性肿块1年余,逐渐长大。右下颌角后下方扪及5×5cm软质肿块,波动感,无触压痛。B超示5.2×3.8cm的囊性病变,边界清;穿刺抽出36ml淡白色液体。诊为腮裂囊肿。抽出囊液,注入复方磷酸液6ml,局部按压,以使药液均匀作用于囊壁,3分钟后冲洗,加压包扎。局部轻度肿胀4天,无明显痛感,因加压包扎不能完全消除死腔,1周后穿刺抽出约10ml暗红色液体。1月复查,未抽出液体,B超示无囊性病变,随访2年无复发。
例四:
尹××,男,51岁,农民,于91年10月28日就诊。上前牙唇侧肿物一年多,流脓半年,肿痛月余,流脓多。
色变黑,唇侧肿物2×2cm,乒乓感,穿刺抽出脓性液体约5ml,X线片示腭前部2×2.5cm透光区,边界清晰。诊为根尖囊肿,穿刺冲洗,无脓性物后,于11月12日注入复方磷酸液4ml,4分钟后抽出复方磷酸液冲洗,因有瘘管,囊腔开放,置碘纺纱条3周,逐渐拆除,5周后复查瘘管消失,穿刺未抽出液体,2年后,X片示无囊样病变区。
例五:
随××,女,23岁,教师,92年2月24日就诊。右下颌角无痛性肿物10余年,逐渐长大,影响面容。肿物位于右下颌角外侧,嚼肌前缘,质软,约3×4cm,压之不能消退,穿刺抽出2ml血液,肿物变小,1分钟后复又肿大充盈。B超示2×2cm的液性占位,边界较清诊为海绵状血管瘤。注入复方磷酸液约1.2ml。次日复查,右下颌角及后方,颌下区有约5×5cm的肿胀区,注射针孔处因药物外漏有0.3×0.2cm的皮肤坏死区,右口角轻度左偏,示颌下缘神经因肿胀受压,开口度及开口型正常,无明显痛感。10天复查抽出约2.5ml淡黄色液体,口角歪斜减轻,1个月复查为2×1.5cm硬质块,2个月为1×1cm,2年复查硬质块消失,B超示无囊样病变。
Claims (2)
1.一种用于治疗囊性肿瘤和血管瘤的复方磷酸液,其特征在于:
a、磷酸为主要成份;
b、盐酸、磷酸二氢钠为辅助成份。
2.根据权利要求1所述的复方磷酸液,其特征在于:磷酸含量为药液的45%;盐酸含量为药液的5%;每100ml药液中磷酸二氢为2g;蒸馏水为药液的50%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 94114274 CN1090942C (zh) | 1994-05-20 | 1994-12-28 | 一种用于治疗囊性肿瘤和血管瘤的复方磷酸液 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN94110601 | 1994-05-20 | ||
CN94110601.2 | 1994-05-20 | ||
CN 94114274 CN1090942C (zh) | 1994-05-20 | 1994-12-28 | 一种用于治疗囊性肿瘤和血管瘤的复方磷酸液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1113760A CN1113760A (zh) | 1995-12-27 |
CN1090942C true CN1090942C (zh) | 2002-09-18 |
Family
ID=25743452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 94114274 Expired - Fee Related CN1090942C (zh) | 1994-05-20 | 1994-12-28 | 一种用于治疗囊性肿瘤和血管瘤的复方磷酸液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1090942C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433716B (zh) * | 2007-11-14 | 2012-05-30 | 安兵 | 治疗恶性实体肿瘤组合物 |
JP2023543858A (ja) * | 2020-09-30 | 2023-10-18 | チェンドゥ クァチャンアオプー メディカル テクノロジー カンパニー リミテッド | 酸-塩基中和合剤を含む医薬組成物及びその使用 |
-
1994
- 1994-12-28 CN CN 94114274 patent/CN1090942C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1113760A (zh) | 1995-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lodha et al. | Role of phenytoin in healing of large abscess cavities | |
CN101209267B (zh) | 红色诺卡氏菌细胞壁骨架在制备治疗皮肤损伤和疮疡的药物中的用途 | |
CN1895600A (zh) | 一种用于治疗腰椎疾病的中药药栓及制作方法 | |
CN1679687A (zh) | 一种治疗妇科疾病外用胶囊及制备方法 | |
CN1090942C (zh) | 一种用于治疗囊性肿瘤和血管瘤的复方磷酸液 | |
EA012294B1 (ru) | Лечебные средства, приготовленные на основе мёда, их применение и способ их получения | |
CN110302228A (zh) | 一种治疗痔疮的生物药剂及其应用 | |
CN109954062A (zh) | 一种活血化瘀、消肿止痛的外用药酒 | |
CN115990232B (zh) | 一种治疗复发性尿路感染的中药组合物及其应用 | |
CN1438006A (zh) | 一种治疗骨科疾病的药物 | |
CN1103230C (zh) | 一种治疗黑痣、雀斑、老年斑、扁平疣的外用膏剂及其制备方法 | |
CN1046634C (zh) | 血管瘤注射液及其制备工艺 | |
RU2692978C1 (ru) | Способ профилактики рубцовых деформаций наружного носа у пациентов с открытой травмой скелета носа | |
Purohit et al. | MANAGEMENT OF STREE ROGAS WSR TO ROLE OF STHANIK CHIKITSA IN DISEASE PATHOGENESIS | |
Badwe et al. | DIABETIC CARBUNCLE A COMPLICATION OF INTRA-ARTICULAR STEROIDAL INJECTION: A CASE STUDY | |
CN106794187A (zh) | 用于骨、软骨、牙齿和牙周组织再生和治疗肿瘤与囊肿的制剂 | |
Shekokar et al. | A case control study of Tilkalka (Sesamum paste) Madhusarpivarti in the management of Vidradhi Bhedana and Vistravana (i & d) | |
CN105168632A (zh) | 一种促进剖宫产伤口愈合的中药涂膜剂及其制备方法 | |
CN1052637C (zh) | 毛莨的用途 | |
CN112353921A (zh) | 一种中药组合物及其用途、制备方法 | |
RU2286162C1 (ru) | Способ лечения кожных проявлений склеродермии | |
CN113521158A (zh) | 一种治疗创面溃烂、疮疡外伤及皮肤病的外用药 | |
CN118217350A (zh) | 一种生肌的药物组合物及其制剂和应用 | |
CN101366717B (zh) | 治疗尖锐湿疣的药物制剂 | |
Tilt | TREATMENT OF UTERINE INFLAMMATION BY INJECTIONS, EXTERNAL APPLICATIONS, BATHS, RESOLUTIVES, COUNTER-IRRITANTS, SEDATIVES, AND DIETETICS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |